D
Dermata Therapeutics, Inc.
DRMACIK 0001853816NasdaqEmerging GrowthPharmaceutical PreparationsDelawareIDFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-7.56M
Total Assets
$7.86M
Equity
$6.22M
Shares Out
4.02M
Op. Cash Flow
$-7.80M
Business
Dermata Therapeutics, Inc. is a late-stage medical dermatology company focused on developing and commercializing topical pharmaceutical candidates based on its proprietary Spongilla technology for medical skin diseases and aesthetic uses. Its main products are XYNGARI™, a once-weekly Spongilla powder mixed with a diluent for treating acne and psoriasis, and DMT410, a Spongilla regimen designed to enable topical delivery of macromolecules such as botulinum toxin. Key activities include clinical development, manufacturing partnerships, IP licensing, and clinical collaborations. It targets dermatologists and patients via clinical trials, third-party manufacturing, and partner-driven commercial channels in the United States and select international markets.
Summary from filing dated 2025-03-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | 8 | 4 | 6 | 3 | |
| Selling, general and administrative (including related party amounts of $645,250 and $0, respectively) | 5 | 4 | — | — | — | |
| Total operating expenses | 8 | 13 | 8 | 10 | — | |
| Loss from operations | −8 | −13 | −8 | −10 | −8 | |
| Interest income | 215,041 | 225,781 | — | — | — | |
| Net loss | −8 | −12 | −8 | −10 | −8 | |
| Net loss per share of Common Stock, basic | −8.16 | −80.32 | — | −0.87 | −2.43 | |
| Net loss per share of Common Stock, diluted | −8.16 | −80.32 | −39.99 | — | — | |
| Weighted-average basic Common Stock | 926,192 | 152,974 | — | — | 4 | |
| Weighted-average diluted Common Stock | 926,192 | 152,974 | 194,928 | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 3 | — | 6 | 11 | |
| Prepaid expenses and other current assets | 341,848 | 372,318 | 540,499 | 703,194 | 825,134 | |
| Total assets | 8 | 4 | 8 | 7 | 12 | |
| Accounts payable (including related party amounts of $86,250 and $0, respectively) | 460,811 | 808,011 | 866,028 | 496,702 | 515,245 | |
| Accrued and other current liabilities (including related party amounts of $25,000 and $0, respectively) | 1 | 1 | 757,588 | 425,932 | — | |
| Total liabilities | 2 | 2 | 2 | 922,634 | 2 | |
| Commitments and Contingencies (see Note 7) | — | — | — | — | — | |
| Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2025, and 2024; 2,660,110 and 251,725 shares issued and outstanding as of December 31, 2025, and 2024, respectively. | 266 | 25 | 26 | 77 | 833 | |
| Additional paid-in capital | 79 | 67 | 60 | 52 | 46 | |
| Accumulated deficit | −73 | −66 | −53 | −46 | −36 | |
| Total stockholders equity | 6 | 2 | 6 | 6 | 10 | |
| Total liabilities and stockholders equity | 8 | 4 | 8 | 7 | 12 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 143,732 | 657,649 | 522,082 | 930,325 | 2 | |
| Prepaid expenses and other current assets | 30,470 | 168,181 | 162,695 | 121,940 | — | |
| Accounts payable | −388,056 | −108,512 | 369,326 | −18,543 | 410,969 | |
| Accrued and other current liabilities | 14,852 | 407,195 | — | — | — | |
| Net cash used in operating activities | −8 | −11 | −6 | −9 | −6 | |
| Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs | 12 | 7 | 8 | 4 | 15 | |
| Payment of prior period issuance costs | −50,495 | — | — | — | — | |
| Proceeds from exercise of pre-funded warrants | 977 | 1,109 | 187 | 287 | — | |
| Payment for fractional shares in reverse stock split | −367 | −828 | −40 | 0 | — | |
| Net cash provided by financing activities | 12 | 7 | 8 | 4 | 16 | |
| Net increase (decrease) in cash and cash equivalents | 4 | −4 | — | — | 10 | |
| Cash paid for taxes | 950 | 950 | 950 | 950 | 1,400 | |
| Issuance of abeyance shares | — | −18 | 0 | — | — | |
| Issuance costs in accounts payable or accrued expenses | 91,352 | 50,495 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro